DE (CLOV)

Role: CEO, Counterpart Health
Signature: /s/ Peter J. Rivas as attorney-in-fact for Conrad Wai
Issuer symbol: CLOV
Transactions as of: 13 Sep 2024
Net transactions value: -$49,562
Form type: 4/A - Amendment
Filing time: 10 Jul 2025, 19:24:38 UTC
Date Of Original Report: 17 Sep 2024
Previous filing: 18 Jun 2024
Next filing: 17 Oct 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wai Conrad	CEO, Counterpart Health	C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON	/s/ Peter J. Rivas as attorney-in-fact for Conrad Wai	10 Jul 2025	0001971702

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLOV	Class A Common Stock	Award	$0	+379,866	+29%	$0.000000	1,699,767	13 Sep 2024	Direct	F1, F2
transaction	CLOV	Class A Common Stock	Sale	$49,562	-15,203	-0.93%	$3.26	1,613,498	08 Jul 2025	By Trust.	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"), each representing a right to a share of Class A Common Stock, earned in connection with the determination of the level of performance achievement in satisfaction of vesting conditions underlying a performance-based restricted share unit grant awarded on October 31, 2023. One-half of the number of earned restricted stock units vested and were settled on September 13, 2024, and the remaining one-half of the restricted stock units will vest on October 31, 2025, subject to the Reporting Person's continued employment on such vesting date. This Amendment is being filed to reflect the full number of RSUs that were achieved.
F2	Number reflects total directly held Class A Common Stock taking into account the amended number and subsequent transactions through July 10, 2025.
F3	The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.27, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4	Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.